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Abstract 26 
Mutations in the gene that encodes the principal L-Carnitine transporter, OCTN2, can lead to a 27 
reduced intracellular L-Carnitine pool and the disease Primary Carnitine Deficiency. L-Carnitine 28 
supplementation is used therapeutically to increase intracellular L-Carnitine. As AMPK and insulin 29 
regulate fat metabolism and substrate uptake we hypothesised that AMPK activating compounds 30 
and insulin would increase L-Carnitine uptake in C2C12 myotubes.  The cells express all three OCTN 31 
transporters at the mRNA level and immunohistochemistry confirmed expression at the protein 32 
level. Contrary to our hypothesis, despite significant activation of PKB and 2DG uptake, insulin did 33 
not increase L-Carnitine uptake at 100nM. However, L-Carnitine uptake was modestly increased at a 34 
dose of 150nM insulin. A range of AMPK activators that increase intracellular calcium content 35 
[caffeine (10mM, 5mM, 1mM, 0.5mM), A23187 (10μM)], inhibit mitochondrial function [Sodium 36 
Azide (75μM), Rotenone (1μM), Berberine (100μM), DNP (500μM)] or directly activate AMPK [AICAR 37 
(250μM)] were assessed for their ability to regulate L-Carnitine uptake. All compounds tested 38 
significantly inhibited L-Carnitine uptake. Inhibition by caffeine was not dantrolene (10μM) sensitive 39 
despite dantrolene inhibiting caffeine mediated calcium release. Saturation curve analysis suggested 40 
that caffeine did not competitively inhibit L-Carnitine transport. To assess the potential role of AMPK 41 
in this process we assessed the ability of the AMPK inhibitor Compound C (10μM) to rescue the 42 
effect of caffeine. Compound C offered a partial rescue of L-Carnitine uptake with 0.5mM caffeine 43 
suggesting that AMPK may play a role in the inhibitory effects of caffeine. However, caffeine likely 44 
inhibits L-Carnitine uptake by alternative mechanisms independently of calcium release. PKA 45 
activation or direct interference with transporter function may play a role. 46 
 47 
48 
  
Introduction  49 
 50 
L-Carnitine [3-Hydroxy-4-(trimethylazaniumyl) butanoate] is a dipeptide compound which acts as a 51 
co-factor for the transport of long chain fatty acids into the mitochondria where they can be oxidized 52 
(12). It is synthesized from methionine and lysine primarily in the liver but also in the brain and 53 
kidneys. 95% of Carnitine in the body is stored within skeletal muscle (6). Carnitine transport into 54 
skeletal muscle cells occurs largely via sodium dependent symport through the Organic Cation 55 
Transporter Novel Type 2 (OCTN2) (40). Primary Carnitine Deficiency is associated with mutations 56 
in the SLC22A4 gene, which codes for OCTN2 and results in a reduced intramuscular L-Carnitine 57 
pool (10, 29). Manifestations of this disorder are either cardiac, skeletal muscle or metabolically 58 
related. The most common diseases associated with each manifestation are; dilated cardiac myopathy, 59 
hypotonia and hypoglycaemia respectively (10, 45). Low L-Carnitine content is particularly damaging 60 
to the heart and leads to a compromised ability to utilise fatty acids for ATP synthesis and can 61 
ultimately lead to heart failure (45). The threshold for the intramuscular pool of L-Carnitine at which 62 
these manifestations occur is yet to be defined. 63 
L-Carnitine supplementation has also been implicated as a way to manipulate carbohydrate and fat 64 
metabolism to improve either exercise performance or metabolic function (48). Indeed there are 65 
studies supporting this in a number of tissues and contexts. For instance: increased L-Carnitine 66 
delivery can have an insulin-mimetic effect on ex vivo tissue (42); dual L-Carnitine and insulin 67 
infusion alters skeletal muscle fuel selection (49); whilst oral L-Carnitine supplementation alters 68 
whole body glucose handling under an OGTT (13). Furthermore, Stephens et al (2013) attributed their 69 
finding of reduced adiposity in subjects fed a caloric surplus plus L-Carnitine to greater fat oxidation 70 
during low intensity exercise due to greater capacity for fatty acid transport and oxidation (52).  L-71 
Carnitine supplementation studies have demonstrated a number of equivocal findings in terms of 72 
exercise performance (46). This is largely believed to be due to the difficulty in altering the 73 
intramuscular L-Carnitine pool. However, in two papers from the same study, (52, 57) it appears that 74 
muscle L-Carnitine content can be elevated when supplemented with high doses of carbohydrate (80g 75 
twice per day), indicating that perhaps insulin may play a role in regulating L-Carnitine uptake and or 76 
  
accumulation. Currently there is a significant gap in the literature concerning the molecular and 77 
pharmacological regulation of L-Carnitine transport into skeletal muscle. 78 
As we mentioned insulin has been proposed to play a role in L-Carnitine transport (or at the very least 79 
accumulation) (52, 57). However, another key regulator of substrate transport, that has to our 80 
knowledge, never been considered as a potential regulator of L-Carnitine transport is AMP-activated 81 
protein kinase (AMPK). Some have speculated that L-Carnitine levels may regulate AMPK function 82 
(14), but this has never been experimentally confirmed. AMPK is a cellular energy sensor activated 83 
by a decrease in the ATP:AMP ratio (18). A decrease in the ATP:AMP ratio leads to the activation of 84 
AMPK during periods of energy stress such as muscle contraction or metabolic toxicity (18). AMPK 85 
acts to restore the ATP:AMP ratio by inhibiting energy consuming pathways (such as protein and 86 
fatty acid synthesis) and activating energy generating pathways (such as glucose uptake and fatty acid 87 
oxidation) (9). The pharmacological activation of AMPK via the AMP mimetic AICAR has 88 
previously been shown to drive substrate uptake including glucose and fatty acids (3, 4, 43, 47). 89 
Similar to AMPK, insulin is well characterised as a driver for glucose (1), amino acid (22) and fatty 90 
acid uptake (32). If AMPK were to drive L-Carnitine uptake then strategies similar to the co-ingestion 91 
of L-Carnitine with carbohydrate (52, 57) could be developed to enhance skeletal muscle L-Carnitine 92 
content.  93 
We hypothesised that insulin and a range of AMPK activating compounds would enhance the 94 
transport of L-Carnitine into C2C12 skeletal muscle myotubes. Contrary to our hypothesis however, we 95 
find that insulin had only a modest effect on L-Carnitine uptake at 150nM, and all AMPK activating 96 
reagents inhibited L-Carnitine uptake. These data have wider implications for the pharmacological 97 
treatment of L-Carnitine deficiency disorders and optimising L-Carnitine accumulation in skeletal 98 
muscle to enhance metabolism. 99 
 100 
 101 
 102 
 103 
  
Methodology 104 
Materials 105 
PKB α/β and γ specific antibodies were sourced from the DSTT (Dundee University) and (AMPK) α1 106 
and α2 specific antibodies were produced by GL Biochem (Shanghai, China) against the following 107 
antigens; α1, CTSPPDSFLDDHHLTR and α2, CMDDSAMHIPPGLKPH. The OCTN1/2/3 antibody 108 
was sourced from Santa Cruz Biotechnology. Radioactive tracers were provided by Hartmann 109 
Analytic. All other reagents and lab consumables were sourced from Fisher Scientific unless 110 
otherwise stated. 111 
Cell culture 112 
C2C12 myoblasts (ATCC) were cultured in 6 or 12 well plates and maintained in a growth media 113 
containing High Glucose Dulbecco’s Modified Eagle Media (DMEM), 20% Fetal Bovine Serum 114 
(FBS) and a 1% Pen/Strep. Once 80-100% confluent the cells were differentiated using a 115 
Differentiating media containing High Glucose DMEM, 2% Donor Horse Serum and 1% Pen/Strep. 116 
Experiments were carried out once cells were fully differentiated into myotubes (3-5 days post 117 
differentiation).  118 
Substrate transport assays 119 
Cells were placed in a serum free media for 3 hours prior to the experiment. Post serum starve the 120 
cells were exposed to a tritiated L-carnitine buffer [100µM (or 0.1µM for insulin stimulation) at 121 
80µCi/µmol] and each treatment was completed with the addition of Insulin (100nM and 150nM) or 122 
one of the following AMPK activators; AICAR [250µM (previously shown to activate AMPK at 123 
500µM) (23)], 2, 4- Dinitrophenol (DNP) [500µM (activates AMPK in L6 myotubes at 500µM) (39)], 124 
Rotenone [1µM (previously demonstrated to activate AMPK in the low µM range) (20)], Berberine 125 
[100µM (30)], Caffeine [5mM (37)], A23187 [10µM (19)] and Sodium Azide [75µM (7)]. Following 126 
3 hour incubation the reaction was stopped using ice cold 0.9% Saline. The cells were lysed using 127 
Sodium hydroxide (NaOH) lysis buffer and collected in Gold Star LT Quanta scintillation fluid 128 
(Meridian Biotechnologies Ltd, Chesterfield, UK) for scintillation counting (United Technologies 129 
Packard 2200CA TriCarb). Uptake data were normalised back to protein content as assessed by 130 
Bradford assays. 131 
  
For glucose uptakes cells were serum starved in serum and amino acid free PBS + 5mM glucose for 3 132 
hr. After the 3 hr serum starve cells were stimulated with or without 100nM insulin for 30mins. 133 
Following the 30min insulin stimulation glucose uptake assays were carried out using a buffer 134 
containing Tritiated 2-Deoxyglucose (10µm at 0.66µCi/ml) for 10mins at room temperature. Ice cold 135 
saline (0.9% NaCl) was used to stop the reaction and cells were lysed using Sodium hydroxide 136 
(NAOH) lysis buffer and added to Gold Star LT Quanta scintillation fluid (Meridian Biotechnologies 137 
Ltd, Chesterfield, UK) for scintillation counting (United Technologies Packard 2200CA TriCarb). 138 
Uptake data were normalised back to protein content as assessed by Bradford assays. 139 
Biochemical assays 140 
All kinase assays were carried out by immunoprecipitation (IP) for 2 h at 4°C as previously described 141 
(35). For immunohistochemistry cells were fixed using 4% formaldehyde in PBS and stored at 4°C. 142 
Slides were blocked in 5% BSA, washed in phosphate-buffered saline (PBS), and exposed overnight 143 
at 4°C to Rabbit OCTN1/2/3 polyclonal antibodies (Santa Cruz Biotechnology, Germany). Sections 144 
were washed in PBS, incubated in the dark at room temperature for 1 h with an Alexa 555–conjugated 145 
goat anti-rabbit immunoglobulin G (IgG; 1:1000; Abcam, Cambridge), and mounted with ﬂuorescent 146 
mounting medium (DAKO) containing DAPI. Slides were stored in the dark at 20°C until 147 
ﬂuorochromes were activated by use of a ﬂuorescent microscope.  148 
For the calcium imaging experiments C2C12 myoblasts were plated onto glass coverslips and then 149 
differentiated to myotubes as described previously.   Differentiated cells were then loaded with 3µM 150 
of the calcium-sensitive dye, Fura-2 (Sigma Aldrich, Dorset, UK) in Locke’s buffer medium [154mM 151 
NaCl, 4mM NaHCO3, 5mM KCl, 2.3mM CaCl2,1mM MgCl2, 5mM glucose, 10mM HEPES (pH 7.4)] 152 
in the presence of 0.025% pluronic F-127 (Life Technologies, Paisley, UK) at 37 °C for 45 min. The 153 
cells were then washed x3 in Locke’s buffer and the coverslips placed into a microscope chamber 154 
containing Locke’s buffer.  The cells were then illuminated with an ultra high point intensity 75-watt 155 
xenon arc lamp (Optosource, Cairn Research, Faversham, Kent, UK) and imaged using a Nikon 156 
Diaphot inverted microscope equipped with a Nikon x40 oil immersion Fluor objective lens (NA = 157 
1.3) and a monochromator (Optoscan, Cairn Research), which was used to alternate the excitation 158 
  
wavelength between 340/380 nm.  Fura-2 fluorescence emission at 510 nm was monitored using a 159 
high resolution interline-transfer cooled digital CCD camera (Cool Snap-HQ, Roper 160 
Scientific/Photometrics, Tucson, AZ). MetaFluor imaging software (Universal Imaging Corp., 161 
Downing, PA) was used for the control of the monochromator, CCD camera, and for processing of the 162 
cell image data. 5mM Caffeine was added after 60 secs using a perfusion system.  To measure the 163 
effect of dantrolene, the cells were preincubated for  20 mins with 10µM dantrolene [demonstrated to 164 
be effective at inhibiting calcium release in L6-myotubes (37)] prior to perfusion of 5mM caffeine.  165 
Ratiometric images captured at 2 sec intervals were then analysed using MetaFluor software. Changes 166 
in calcium were expressed as fold changes over normalised basal calcium for each cell.  Data was 167 
collected for 23-33 cells over 3 separate experiments and statistical difference between mean maximal 168 
caffeine-induced calcium responses in the presence and absence of dantrolene analysed using a 2-169 
tailed unpaired t-test using Excel, with significance determined as p<0.05.  170 
Primers for PCR analysis were designed from reference sequences using Primer 3 (ref). RNA was 171 
extracted from C2C12 cells using Trizol reagent (Invitrogen) following standard protocols. 1ug of 172 
total RNA was reverse transcribed using oligo dT primers. Buffer, reverse transcriptase, dNTPs and 173 
RNAse inhibitor were combined as directed by the manufacturer (RevertAid RT kit – Fisher) and 8ul 174 
added to each RNA/oligo dT cocktail. Reactions were incubated for 60 min at 42°C with a final 175 
termination step of 70°C for 5 min. cDNA was stored at -20oC before use. Amplification of gene 176 
products was carried out using the Fermentas PCR kit (Fermentas, Thermo-Scientific, UK). Briefly 177 
1ul of cDNA was combined with 12.5ul supplied PCR master mix, 1ul of forward and reverse primer 178 
each at 10μM and 9.5ul ddH2O. The reactions conditions were 95ºC for 1min, 35 cycles of 95ºC for 179 
30s, 50ºC for 30s and 72ºC for 60s followed by a final 5 mins at 72ºC. Products were visualised by 180 
agarose gel electrophoresis in 1% agarose gel. Electrophoresis was carried out for 40 mins at 100V. 181 
Bands were imaged with a BioRad gel doc system (Biorad, UK) 182 
 183 
  
Statistics 184 
Unless otherwise stated, Figures and Statistical analyses were carried out using the Graph Pad Prism 4 185 
platform. Paired T-tests or repeated measures ANOVA with a post hoc Tukey’s HSD test were used 186 
to determine significance between control and treatment groups.  187 
  188 
  
Results 189 
C2C12 myotubes express OCTN1/2/3 190 
Previous work has shown that primary human myotubes and C2C12 myoblasts and myotubes transport 191 
L-Carnitine (15, 34). However, to ensure that our C2C12 model would be a useful tool to study L-192 
Carnitine transport we first assessed if the OCTN family of transporters that shuttle L-Carnitine into 193 
the cell were present in the C2C12 cell line. We carried out PCR reactions to test for the presence of the 194 
OCTN1/2/3 transcript isoforms with isoform-specific primers. PCR products at the predicted weights 195 
were found for all three sets of primers indicating the presence of OCTN1/2/3 mRNA (Figure1A). To 196 
confirm expression at the protein level, we carried out immunohistochemistry experiments with a pan-197 
OCTN1/2/3 antibody and identified that C2C12 myotubes expressed some or all of these isoforms at 198 
the protein level. Staining can be seen throughout the identified myotube membrane indicating the 199 
presence of the transporter. (Figure1B).  200 
L-Carnitine uptake and insulin 201 
Insulin stimulates the uptake of glucose (1) and small neutral amino acids by activating the systemA 202 
transport system (22). We hypothesised that insulin may also regulate the transport of L-Carnitine. 203 
We first confirmed that our cells were insulin responsive by demonstrating insulin- stimulated PKB 204 
activation and glucose uptake (Figure 2A and 2B). Despite the obvious insulin responsiveness of our 205 
cell line, we found that 100nM did not have a significant effect on L-Carnitine uptake, however 206 
150nM insulin did induce a modest but significant increase in uptake (Figure 2C).  207 
AMPK activation by a range of confirmed AMPK activators 208 
From previous studies we know that AMPK, like insulin, drives substrate uptake (3-5, 47). With this 209 
in mind, we aimed to evaluate the potential role of AMPK in L-Carnitine uptake. First however, we 210 
identified 7 ‘AMPK activating compounds’ and determined their ability to induce AMPK activity in 211 
C2C12 myotubes. All compounds tested significantly activated AMPK after a 30 minute stimulation 212 
period to varying degrees ranging from 2.2 ± 0.58 fold to 5.42 ± 0.48 fold (Figure 3B). Having 213 
confirmed that each compound significantly activates AMPK we next evaluated the effect of these 214 
compounds on L-Carnitine uptake (Figure 3A).  Contrary to our hypothesis, treatment of C2C12 215 
  
myotubes with these compounds results in a significant reduction in L-Carnitine uptake in all 216 
treatment conditions to varying degrees from 32.61 ± 3.05 % reduction to 81.16 ± 5.85 % reduction.  217 
Exploring the mechanism of caffeine mediated L-Carnitine uptake 218 
There was a linear relationship between the degree of activation of AMPK and the degree of 219 
inhibition of L-Carnitine uptake (data not shown), however caffeine was a substantial outlier on this 220 
curve and so we further explored the mechanism of action of caffeine on L-Carnitine uptake. 221 
Although caffeine is not an organic cation, we performed a substrate-saturation curve to assess if 222 
caffeine could be inhibiting uptake via competitive inhibition of transport, as expected the kinetic 223 
curve revealed that the predicted Vmax was reduced indicating non-competitive inhibition (Figure 4A). 224 
Further analysis of inhibition across a range of substrate concentrations revealed a dose dependent 225 
effect of caffeine across all substrate concentrations tested (Figure 4B). To test the calcium 226 
dependence of the effects of caffeine we assessed the impact of 10μM dantrolene on the reversibility 227 
of the inhibition effect of caffeine. As expected dantrolene had no impact on the inhibitory effect of 228 
A23187 (a calcium ionophore), however neither did it reverse the inhibitory effects of caffeine 229 
(Figure 4C). To test if a lower dose of caffeine could be reversed by dantrolene we halved the dose of 230 
caffeine to 5mM and again dantrolene did not rescue the uptake inhibition (Figure 4D). This is in spite 231 
of our findings that dantrolene substantially inhibited the appearance of calcium in response to 232 
caffeine stimulation (Figure 4E). We next assessed if the inhibitory effect was dependent upon AMPK 233 
by using the inhibitor Compound C. These data revealed a partial rescue of Carnitine transport at a 234 
relatively low dose of caffeine (0.5mM) but not at the higher dose of caffeine (5mM) suggesting 235 
potential alternative mechanisms in the control of L-Carnitine transport.      236 
  
Discussion 237 
The transport of L-Carnitine into skeletal muscle is an essential process for optimal metabolic 238 
functioning. The inability to transport L-Carnitine efficiently is associated with Primary Carnitine 239 
Deficiency, muscle weakness and in C2C12 myotubes is associated with impaired growth (15). L-240 
Carnitine transport into skeletal muscle cell lines has two transport affinities, one at a high affinity 241 
within the physiological range for L-Carnitine and a low affinity transport activity that works at 242 
higher non-physiological ranges (15, 34). Here we investigated the pharmacological regulation of L-243 
Carnitine uptake in C2C12 myotubes across these affinity ranges for L-Carnitine transport during 244 
pharmacologically induced energy stress and in response to insulin. For the first time we demonstrate 245 
that both direct and indirect AMPK activators inhibit the uptake of L-Carnitine into the cytosol of 246 
C2C12 myotubes in a manner independent of calcium release and partially sensitive to the AMPK 247 
inhibitor Compound C. In addition, we provide evidence that insulin regulates L-Carnitine uptake in 248 
this skeletal muscle model at the L-Carnitine concentrations we used.  249 
It is well documented that AMPK and insulin drive glucose and fatty acid uptake in striated muscle 250 
(3-5, 32, 47). Additionally, insulin directly regulates the uptake of small neutral amino acids (22). 251 
Given the role of L-Carnitine in fatty acid metabolism (48), and the role that AMPK plays in 252 
promoting whole body fatty acid flux (21) we hypothesised that both insulin and AMPK would 253 
stimulate L-Carnitine uptake. However, we found that an inverse relationship existed between AMPK 254 
activation and L-Carnitine uptake and this raises the question as to why AMPK activators and 255 
potentially AMPK inhibit L-Carnitine uptake? L-Carnitine uptake in skeletal muscle is oubain 256 
sensitive and dependent upon extracellular sodium (15). Therefore the Na+/K+ATPase is required for 257 
skeletal muscle L-Carnitine uptake, it is therefore possible that AMPK activation or energy stress may 258 
influence the Na+ gradient required for transport (15). However, energy stress and specifically AMPK 259 
activation in skeletal muscle enhances the activity of the Na+/K+ATPase (2). As a result it is unlikely 260 
that the compounds would have been working through the inhibition of the Na+ gradient. It has been 261 
speculated however, that the insulin dependent activation of the Na+/K+ATPase may be responsible 262 
for the increased L-Carnitine accumulation/retention noted in human studies where L-Carnitine is fed 263 
in conjunction with large doses of carbohydrate (51, 57) or infused with physiologically high insulin 264 
  
concentrations (50). However, none of these studies directly assessed L-Carnitine transport. One study 265 
however, demonstrated improved L-Carnitine balance across the forearm following the consumption 266 
of 80g of carbohydrate (44). The present study has shown that at the most basic level, in cell culture, 267 
insulin does not affect the transport of L-Carnitine in skeletal muscle unless a relatively high dose of 268 
insulin (150nM vs 100nM) is utilized. Whilst in humans, insulin has not been shown to affect L-269 
Carnitine uptake but rather balance and accumulation, our data suggests that perhaps if insulin 270 
achieves a high enough concentration it could modify skeletal muscle uptake. 271 
Analogues of L-Carnitine including mildronate have the capacity to inhibit transport in skeletal 272 
muscle (15). Therefore, some of the compounds may inhibit L-Carnitine uptake by competitive 273 
inhibition through shared transport mechanisms. For instance Berberine has been shown to not only 274 
be a potent AMPK activator (8, 25, 28, 31, 33) but also to be a substrate for and inhibitor of the sub-275 
family of OCTN related transporters OCT2/3 with an IC50 of 0.1-10 μM in MDCK cells transfected 276 
with hOCT2/3 (54). Metformin is also transported via a similar mechanism (38) and we avoided the 277 
use of this compound for that reason. Therefore the inhibition of L-Carnitine uptake with 100μM 278 
Berberine could be due to competitive inhibition. Analysis of over expressed OCT transcripts in 279 
transport models has revealed that OCT transporters transport a wide range of structurally diverse 280 
compounds (24). Some evidence suggests that a positive charge is also not obligatory for transport 281 
(26). Typically however, they have been reported to transport small (60-350 Da) water soluble 282 
compounds, usually containing a positively charged amine at physiological pH (24). The transport 283 
function of the OCTN subfamily, however is far less characterised, but OCTN2 has undergone 284 
extensive testing for compounds that could interfere with transport function (56). These data suggest 285 
that a permanent positive charge is important but not entirely necessary to inhibit OCTN2 function 286 
(56). The metabolic toxins used in this study (DNP, rotenone, azide) have never been assessed as 287 
substrates of OCTN transporters, as far as we know. Additionally they are not cations. Therefore, the 288 
mechanism of inhibition by these compounds is unlikely to be via competitive inhibition of transport, 289 
but cannot be ruled out entirely. One potential mechanism could be due to the effect that 290 
mitochondrial toxins would have on enhancing glycolysis. The increased dependence upon glycolysis 291 
and anaerobic respiration would lead to an acidification of the cellular environment which could cause 292 
  
an inhibition of L-Carnitine transport which requires an optimal pH range to function fully (15). One 293 
interesting aspect however, is that OCTN1 has been identified as having a nucleotide-binding site and 294 
displays transport function inhibited by ATP depletion by glycolytic inhibitors and mitochondrial 295 
toxins (55). These data suggest that transport of L-Carnitine by OCTN1, at least, could be inhibited 296 
directly by reductions in ATP. This could also be a potential mechanism by which the AMP mimetic 297 
AICAR could work. If ZMP instead of ATP occupies the nucleotide-binding site it may impair 298 
function. However, it must be stated that the nucleotide dependency of OCTN transporters has never 299 
been confirmed nor has the ability of AMP to regulate function.  300 
All of the compounds mentioned above, must be transported into the cell to act on various 301 
intracellular molecules or directly on the mitochondria. Due to the broad range of molecules that 302 
could act as substrates (56) for the OCTN transport mechanisms that transport L-Carnitine it is 303 
possible that the above compounds could interfere as competitive inhibitors of transport. The calcium 304 
release compounds however, act either by increasing the permeability of the plasma membrane to 305 
Ca2+ (41) or by inducing Ca2+ release from the sarcoplasmic reticulum (53). Both are lipophilic 306 
molecules capable of diffusing across the membrane independently of active transport mechanisms 307 
(11, 41) and therefore competitive inhibition is unlikely to be the mode of action. Both molecules 308 
significantly activated AMPK by ~2fold and both molecules inhibited L-Carnitine uptake by ~50% 309 
(A23187) and ~80% (caffeine). Dantrolene (10μM) which inhibits the release of calcium from 310 
intracellular stores (27) significantly inhibited calcium release with 5mM caffeine, surprisingly it did 311 
not rescue the inhibitory effect of caffeine on L-Carnitine uptake. These data suggested that the 312 
influence of caffeine, at least, was independent of changes in Ca2+. We therefore assessed the impact 313 
of caffeine on L-Carnitine transport kinetics, which confirmed that caffeine was non-competitively 314 
inhibiting transport. We next tested the dependency of the inhibitory effects of caffeine on AMPK 315 
with the AMPK inhibitor Compound C (10μM). Compound C did not rescue the effect of caffeine at 316 
high doses (5mM) but did partially recover uptake at a much lower dose of caffeine (0.5mM) 317 
suggesting that the inhibition of uptake was at least partially dependent upon AMPK. 318 
  
It is clear from these data that alternative caffeine sensitive mechanisms exist in the inhibition of L-319 
Carnitine transport. Caffeine also inhibits phosphodiesterases influencing cAMP levels (36). cAMP 320 
activates PKA and the effects of caffeine on drosophila brain have been shown to be sensitive to PKA 321 
inhibitors (58). Therefore in addition to AMPK, there could be a role for PKA in the effects of 322 
caffeine on L-Carnitine transport and it would therefore be interesting to assess the influence of 323 
forskolin, a PKA activator, on L-Carnitine transport. Alternatively, caffeine could be interfering with 324 
transport function through an as yet unidentified mechanism. Regardless of the mechanism, our data 325 
showed that caffeine was inhibitory as low as 500μM. Human supplementation studies (16, 17) 326 
demonstrate that following a dose of caffeine in the range of 5-6mg/kg, caffeine can reach a plasma 327 
concentration of ~30μM. With oral dosing this concentration would be much higher in the portal vein 328 
and therefore chronic exposure to caffeine dosing could conceivably interfere with L-Carnitine 329 
accumulation in the liver and potentially the skeletal muscle. Further work should explore the 330 
influence that caffeine and other AMPK activators have on L-Carnitine balance in metabolically 331 
active tissues.   332 
In conclusion, this study is the first to show that insulin in a relative high dose modestly increases L-333 
Carnitine transport into a skeletal muscle cell line. Additionally, we demonstrate that AMPK 334 
activators do not drive L-Carnitine uptake but rather substantially inhibit uptake. While we were 335 
unable to confirm whether AMPK was required for inhibition by these compounds we were able to 336 
demonstrate that the inhibitory effects of caffeine are independent of calcium release and partially 337 
sensitive to the AMPK inhibitor Compound C.  338 
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Table 1. Primer details for M. musculus Octn amplification. 504 
Primer Sequence 
MmOctn1_F GGTGGAAACATGCGGGACTA
MmOctn1_R GATGATGCGAACCGACTTGC 
Mm_Octn2_F CCACGGTGTCCCCTTATTCC
Mm_Octn2_R TTGCGACCAAACCTGTCTGA 
Mm_Octn3_F CGACGCTTTCTCGAACTCCT
Mm_Octn3_R CACCATGAAGCCAAACGCAA 
 505 
  506 
  
Figure Legends. 507 
Figure 1. Expression of Carnitine transporter isoforms in C2C12 myotubes. PCR amplification 508 
demonstrates the expression of the three OCTN isoforms in C2C12 myotubes (A). 509 
Immunohistochemical analysis with a pan OCTN1/2/3 antibody demonstrates expression at the 510 
protein level (B). Blue indicates DAPI staining of the nucleus and red indicates OCTN1/2/3. 511 
Figure 2. Insulin mediated Carnitine transport. C2C12 myotubes were serum starved in PBS 512 
containing 5mM glucose for 2hrs followed by a 30min stimulation with insulin to assess PKB activity 513 
(A), 2DG uptake (B) and L-Carnitine transport (n=4). * indicates significantly different from baseline 514 
(p<0.05). 515 
Figure 3. AMPK activators inhibit L-Carnitine transport. Cells were treated with AICAR (250μM), 516 
Azide (75μM), Berberine (100μM), DNP (500μM), Caffeine (10mM), A23187 (10μM) and L-517 
Carnitine transport determined (A) and AMPK activity assessed (B). Compounds were present 518 
throughout the uptake assay and data are normalised to each respective control. *indicates 519 
significantly different from baseline. 520 
Figure 4. Caffeine inhibits L-Carnitine transport independently of calcium release. Uptake kinetics 521 
were assessed with increasing amounts of tracee in the presence or absence of 5mM caffeine (A). 522 
Inhibition by caffeine was assessed with 1 or 5mM caffeine at 100, 50, 10 or 0.1μM L-Carnitine (B).  523 
Cells were pre-treated with dantrolene (10μM) prior to the addition of caffeine during the uptake and 524 
calcium imaging experiments. Caffeine (10mM) or A23187 (10μM) were added following a 10min 525 
pre-incubation with dantrolene (10μM) and L-Carnitine uptake assessed. Data are represented as % of 526 
baseline (C). L-Carnitine uptake was assessed with 0mM, 5mM caffeine and 10mM caffeine with or 527 
without 10μM dantrolene (D). Calcium release was assessed as described in the methods with 5mM 528 
caffeine with or without 10μM dantrolene (E). Uptake of L-Carnitine was assessed with 0.5mM or 529 
5mM caffeine in the presence or absence of 10μM compound C (F). * indicates significantly different 530 
from baseline, # indicates significantly different from 1mM caffeine. α indicates significantly 531 
different from 5mM caffeine at peak, δ indicates significantly different from 5mM caffeine at 60mins.  532 
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